Acarbose

Generic Name: Acarbose

Brand Names: Precose

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₄₃NO_₁₈

CAS Number: 56180-94-0

Unique Ingredient Identifier: T58MSI464G

Background: Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex...

Indication: Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: insulin glargine
Other: Standard glycemic care
Drug: metformin
Drug: acarbose
Behavioral: lifestyle therapy

First Posted Date: 2010-08-13

Last Posted Date: 2020-05-21

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 83

Registration Number: NCT01181674

Locations: 🇨🇦
McMaster University Medical Centre, Diabetes Care and Research Program, Hamilton, Ontario, Canada

Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin phosphate
Drug: Acarbose
Drug: Glimepiride

First Posted Date: 2010-08-09

Last Posted Date: 2018-08-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 380

Registration Number: NCT01177384

Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy

Phase 4

Conditions: Diabetes

Interventions: Drug: Actos (Pioglitazone)
Drug: Acarbose

First Posted Date: 2010-08-04

Last Posted Date: 2011-01-05

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 200

Registration Number: NCT01175486

Locations: 🇨🇳
Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Nateglinide
Drug: Acarbose

First Posted Date: 2009-12-14

Last Posted Date: 2012-10-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 103

Registration Number: NCT01030952

Locations: 🇨🇳
Shanghai Sixth People's Hospital, 600 Xuanshan Road, Shanghai, China
🇨🇳
Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, China
🇨🇳
Shanghai Tongji Hospital, 389 Xinchun Road, Shanghai, China

The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin

Phase 4

Conditions: Chronic Hepatitis C

Interventions: Drug: Pioglitazone
Drug: Acarbose
Drug: Metformin

First Posted Date: 2009-12-04

Last Posted Date: 2012-11-27

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 80

Registration Number: NCT01025765

Locations: 🇨🇳
National Taiwan University Hospital Department of Internal Medicine,, Taipei, Taiwan

Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

Not Applicable

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Rosiglitazone
Drug: Acarbose

First Posted Date: 2009-11-25

Last Posted Date: 2022-01-20

Lead Sponsor: Jean-Patrice Baillargeon

Target Recruit Count: 52

Registration Number: NCT01019356

Locations: 🇨🇦
Université de Sherbrooke, Sherbrooke, Quebec, Canada

Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)

Phase 4

Conditions: Diabetes Mellitus
Impaired Glucose Tolerance
Coronary Artery Disease

Interventions: Drug: acarbose

First Posted Date: 2009-03-10

Last Posted Date: 2012-07-18

Lead Sponsor: Aichi Gakuin University

Target Recruit Count: 150

Registration Number: NCT00858676

Locations: 🇯🇵
Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University, Nagoya, Japan

Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity

Phase 4

Terminated

Conditions: Pediatric Obesity
Insulin Resistance
Impaired Glucose Tolerance
Cardiovascular Disease

Interventions: Drug: Acarbose

First Posted Date: 2009-02-18

Last Posted Date: 2013-05-01

Lead Sponsor: Yale University

Target Recruit Count: 23

Registration Number: NCT00846521

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Acarbose Cardiovascular Evaluation Trial

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus (T2DM)
Coronary Heart Disease
Acute Coronary Syndrome
Impaired Glucose Tolerance

Interventions: Drug: Matching Placebo
Drug: Acarbose

First Posted Date: 2009-01-27

Last Posted Date: 2017-07-25

Lead Sponsor: University of Oxford

Target Recruit Count: 6526

Registration Number: NCT00829660

Locations: 🇨🇳
Shanghai Zhabei District Shibei Hospital, Shanghai, Shanghai, China
🇨🇳
China Meitan General Hospital, Beijing, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

and more 173 locations

A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 2

Terminated

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: Acarbose

First Posted Date: 2008-05-14

Last Posted Date: 2013-08-19

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 1

Registration Number: NCT00677521

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy